Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ipsen
Age
55–80
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female subjects 55 to 80 years with histologically or cytologically documented primary intraductal or lobular invasive breast cancer that meets the following criteria:
T2, N0 or N1, M0.
Primary tumour clinically determined to be 2 to 5 cm in the greatest dimension.
Laboratory documentation of positive oestrogen receptor (ER+) status in at least 10% of the tumour cells.
Laboratory documentation of HER-2 negative status.
Postmenopausal defined as
no spontaneous menses for a total of 2 years
amenorrheic for at least 12 months with serum oestrogen level \<30 pg/mL, and both luteinising hormone (LH)/follicle stimulating hormone (FSH) \>20 IU/L, chemotherapy-induced amenorrhoea for at least 12 months
bilateral oophorectomy, or radiation castration and amenorrhoeic for at least 3 months.
Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
You may not be if
Has locally advanced breast cancer that is considered non-operable without neoadjuvant therapy.
Has evidence of metastatic disease
as a diagnosis of inflammatory breast cancer
Has ductal carcinoma in situ
Clareo Health | Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast Cancer
